サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1387441

エピジェネティック医薬品・診断技術市場レポート：2030年までの動向、予測、競合分析

Epigenetic Drug and Diagnostic Technology Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日: | 発行: Lucintel | ページ情報: 英文 150 Pages | 納期: 3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円

ご注意:　DRM (デジタル著作権管理システム) 付PDFになります。
制限内容は、上記ライセンスの[詳細]アイコンをクリックしてご確認ください。

エピジェネティック医薬品・診断技術市場レポート：2030年までの動向、予測、競合分析
出版日: 2023年11月01日
発行: Lucintel
ページ情報: 英文 150 Pages
納期: 3営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

エピジェネティック医薬品・診断技術の動向と予測

世界のエピジェネティック医薬品・診断技術市場は、2024年から2030年までのCAGRが19.2%で、2030年までに推定277億米ドルに達すると予測されます。この市場の主な促進要因は、がんや神経疾患などの慢性疾患の有病率の上昇、高齢人口の急増、新しいエピジェネティック医薬品・診断技術の革新です。世界のエピジェネティック医薬品・診断技術市場の将来は、がん領域および非がん領域市場における機会により有望視されています。

エピジェネティック医薬品・診断技術市場の洞察

Lucintel社は、DNMTは広く利用可能であるため、予測期間中、より大きなセグメントであり続けると予測しています。

この市場の中では、がんの高成長とがんによる死亡者数の増加により、がん領域がより大きなセグメントであり続けるでしょう。

北米は確立されたヘルスケア施設の存在と老年人口の急増により、予測期間中も最大地域であり続けると思われます。

本レポートでは、以下の11の主要な質問に回答している：

  • Q.1.市場セグメントのうち、最も有望かつ高成長な機会は何か？
  • Q.2.どのセグメントがより速いペースで成長するのか、またその理由は？
  • Q.3.今後成長が加速すると思われる地域とその理由は？
  • Q.4.市場力学に影響を与える主な要因は何か？市場における主な課題とビジネスリスクは？
  • Q.5.この市場におけるビジネスリスクと競合の脅威は？
  • Q.6.この市場における新たな動向とその理由は？
  • Q.7.市場における顧客の需要の変化にはどのようなものがありますか？
  • Q.8.この市場における新たな開発と、その開発をリードしている企業は？
  • Q.9.この市場における主要企業は？主要企業は事業成長のためにどのような戦略的取り組みを進めているのか？
  • Q.10.この市場における競合製品にはどのようなものがあり、材料や製品の代替による市場シェア低下の脅威はどの程度ありますか？
  • Q.11.過去5年間にどのようなM&Aが行われ、業界にどのような影響を与えましたか？

目次

第1章 エグゼクティブサマリー

第2章 世界のエピジェネティック医薬品・診断技術市場：市場力学

  • イントロダクション、背景、分類
  • サプライチェーン
  • 業界の促進要因と課題

第3章 2018年から2030年までの市場動向と予測分析

  • マクロ経済動向（2018～2023年）と予測（2024～2030年）
  • 世界のエピジェネティック医薬品・診断技術市場動向（2018-2023）および予測（2024-2030）
  • 治療タイプ別の世界のエピジェネティック医薬品・診断技術市場
    • HDAC
    • DNMT
  • 技術別の世界のエピジェネティック医薬品・診断技術市場
    • DNAメチル化
    • ヒストンのメチル化
    • ヒストンのアセチル化
    • 大きな非コードRNA
    • ミクロRNAの修飾
    • クロマチンの構造
  • 用途別の世界のエピジェネティック医薬品・診断技術市場
    • 腫瘍学
    • 非腫瘍学

第4章 2018年から2030年までの地域別の市場動向と予測分析

  • 地域別の世界のエピジェネティック医薬品・診断技術市場
  • 北米のエピジェネティック医薬品・診断技術市場
  • 欧州のエピジェネティック医薬品・診断技術市場
  • アジア太平洋のエピジェネティック医薬品・診断技術市場
  • その他地域エピジェネティック医薬品・診断技術市場

第5章 競合の分析

  • 製品ポートフォリオ分析
  • 運用上の統合
  • ポーターのファイブフォース分析

第6章 成長機会と戦略的分析

  • 成長機会分析
    • 治療タイプ別の世界のエピジェネティック医薬品・診断技術市場の成長機会
    • 技術別の世界のエピジェネティック医薬品・診断技術市場の成長機会
    • 用途別の世界のエピジェネティック医薬品・診断技術市場の成長機会
    • 地域別の世界のエピジェネティック医薬品・診断技術市場の成長機会
  • 世界のエピジェネティック医薬品・診断技術市場の新たな動向
  • 戦略的分析
    • 新製品の開発
    • 世界のエピジェネティック医薬品・診断技術市場の能力拡大
    • 世界のエピジェネティック医薬品・診断技術市場における合併、買収、合弁事業
    • 認証とライセンシング

第7章 有力企業の企業プロファイル

  • Roche Diagnostics
  • Thermo Fisher Scientific
  • Eisai
  • Novartis
  • Illumina
  • Merck Sharp & Dohme
  • Qiagen
目次

Epigenetic Drug and Diagnostic Technology Trends and Forecast

The future of the global epigenetic drug and diagnostic technology market looks promising with opportunities in the oncology and non-oncology markets. The global epigenetic drug and diagnostic technology market is expected to reach an estimated $27.7 billion by 2030 with a CAGR of 19.2% from 2024 to 2030. The major drivers for this market are rising prevalence of chronic diseases like cancer and neurological disorders, surge in geriatric population, and innovations of new epigenetic drugs and diagnostics technologies.

A more than 150-page report is developed to help in your business decisions.

Epigenetic Drug and Diagnostic Technology by Segment

The study includes a forecast for the global epigenetic drug and diagnostic technology by type of therapy, technology, application, and region.

Epigenetic Drug and Diagnostic Technology Market by Type of Therapy [Shipment Analysis by Value from 2018 to 2030]:

  • HDAC
  • DNMT

Epigenetic Drug and Diagnostic Technology Market by Technology [Shipment Analysis by Value from 2018 to 2030]:

  • DNA Methylation
  • Histone Methylation
  • Histone Acetylation
  • Large Noncoding RNA
  • Microrna Modification
  • Chromatin Structures

Epigenetic Drug and Diagnostic Technology Market by Application [Shipment Analysis by Value from 2018 to 2030]:

  • Oncology
  • Non-Oncology

Epigenetic Drug and Diagnostic Technology Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Epigenetic Drug and Diagnostic Technology Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies epigenetic drug and diagnostic technology companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the epigenetic drug and diagnostic technology companies profiled in this report include-

  • Roche Diagnostics
  • Thermo Fisher Scientific
  • Eisai
  • Novartis
  • Illumina
  • Merck Sharp & Dohme
  • Qiagen

Epigenetic Drug and Diagnostic Technology Market Insights

Lucintel forecasts that DNMT will remain the larger segment over the forecast period due to wide-scale availability.

Within this market, oncology will remain the larger segment due to high growth of cancer and rising number of deaths caused by cancer.

North America will remain the largest region over the forecast period due to presence of well established healthcare facilities and surge in geriatric population in the region.

Features of the Global Epigenetic Drug and Diagnostic Technology Market

Market Size Estimates: Epigenetic drug and diagnostic technology market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Epigenetic drug and diagnostic technology market size by type of therapy, technology, application, and region in terms of value ($B).

Regional Analysis: Epigenetic drug and diagnostic technology market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different type of therapy, technologies, applications, and regions for the epigenetic drug and diagnostic technology market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the epigenetic drug and diagnostic technology market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the epigenetic drug and diagnostic technology market size?

Answer: The global epigenetic drug and diagnostic technology market is expected to reach an estimated $27.7 billion by 2030.

Q2. What is the growth forecast for epigenetic drug and diagnostic technology market?

Answer: The global epigenetic drug and diagnostic technology market is expected to grow with a CAGR of 19.2% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the epigenetic drug and diagnostic technology market?

Answer: The major drivers for this market are rising prevalence of chronic diseases like cancer and neurological disorders, surge in geriatric population, and innovations of new epigenetic drugs and diagnostics technologies.

Q4. What are the major segments for epigenetic drug and diagnostic technology market?

Answer: The future of the epigenetic drug and diagnostic technology market looks promising with opportunities in the oncology and non-oncology markets.

Q5. Who are the key epigenetic drug and diagnostic technology market companies?

Answer: Some of the key epigenetic drug and diagnostic technology companies are as follows:

  • Roche Diagnostics
  • Thermo Fisher Scientific
  • Eisai
  • Novartis
  • Illumina
  • Merck Sharp & Dohme
  • Qiagen

Q6. Which epigenetic drug and diagnostic technology market segment will be the largest in future?

Answer: Lucintel forecasts that DNMT will remain the larger segment over the forecast period due to wide-scale availability.

Q7. In epigenetic drug and diagnostic technology market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to presence of well established healthcare facilities and surge in geriatric population in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the epigenetic drug and diagnostic technology market by type of therapy (HDAC and DNMT), technology (DNA methylation, histone methylation, histone acetylation, large noncoding RNA, microrna modification, and chromatin structures), application (oncology and non-oncology), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Epigenetic Drug and Diagnostic Technology Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Epigenetic Drug and Diagnostic Technology Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Epigenetic Drug and Diagnostic Technology Market by Type of Therapy
    • 3.3.1: HDAC
    • 3.3.2: DNMT
  • 3.4: Global Epigenetic Drug and Diagnostic Technology Market by Technology
    • 3.4.1: DNA Methylation
    • 3.4.2: Histone Methylation
    • 3.4.3: Histone Acetylation
    • 3.4.4: Large Noncoding RNA
    • 3.4.5: Microrna Modification
    • 3.4.6: Chromatin Structures
  • 3.5: Global Epigenetic Drug and Diagnostic Technology Market by Application
    • 3.5.1: Oncology
    • 3.5.2: Non-oncology

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Epigenetic Drug and Diagnostic Technology Market by Region
  • 4.2: North American Epigenetic Drug and Diagnostic Technology Market
    • 4.2.2: North American Epigenetic Drug and Diagnostic Technology Market by Application: Oncology and Non-oncology
  • 4.3: European Epigenetic Drug and Diagnostic Technology Market
    • 4.3.1: European Epigenetic Drug and Diagnostic Technology Market by Type of Therapy: HDAC and DNMT
    • 4.3.2: European Epigenetic Drug and Diagnostic Technology Market by Application: Oncology and Non-oncology
  • 4.4: APAC Epigenetic Drug and Diagnostic Technology Market
    • 4.4.1: APAC Epigenetic Drug and Diagnostic Technology Market by Type of Therapy: HDAC and DNMT
    • 4.4.2: APAC Epigenetic Drug and Diagnostic Technology Market by Application: Oncology and Non-oncology
  • 4.5: ROW Epigenetic Drug and Diagnostic Technology Market
    • 4.5.1: ROW Epigenetic Drug and Diagnostic Technology Market by Type of Therapy: HDAC and DNMT
    • 4.5.2: ROW Epigenetic Drug and Diagnostic Technology Market by Application: Oncology and Non-oncology

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Epigenetic Drug and Diagnostic Technology Market by Type of Therapy
    • 6.1.2: Growth Opportunities for the Global Epigenetic Drug and Diagnostic Technology Market by Technology
    • 6.1.3: Growth Opportunities for the Global Epigenetic Drug and Diagnostic Technology Market by Application
    • 6.1.4: Growth Opportunities for the Global Epigenetic Drug and Diagnostic Technology Market by Region
  • 6.2: Emerging Trends in the Global Epigenetic Drug and Diagnostic Technology Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Epigenetic Drug and Diagnostic Technology Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Epigenetic Drug and Diagnostic Technology Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Roche Diagnostics
  • 7.2: Thermo Fisher Scientific
  • 7.3: Eisai
  • 7.4: Novartis
  • 7.5: Illumina
  • 7.6: Merck Sharp & Dohme
  • 7.7: Qiagen